The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial
Abstract
BACKGROUND: Randomized trials of postmenopausal hormone therapy have found differing effects on fasting glucose levels. No trial has evaluated the effect of hormone therapy on diabetes incidence. OBJECTIVE: To evaluate the effect of hormone therapy on fasting glucose level and incident diabetes. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: 20 U.S. clinical centers. PARTICIPANTS: 2763 postmenopausal women with coronary heart disease who were followed for 4.1 years. At baseline, 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglycemic; the 2029 women without diabetes were followed for incident diabetes. INTERVENTION: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily, or placebo. MEASUREMENTS: Fasting glucose level was measured at baseline, at year 1, and at the end of the trial. Incident diabetes was defined by self-report of diabetes or disease complication, fasting glucose level of 6.9 mmol/L or greater (> or =126 mg/dL), or initiation of therapy with diabetes medication. RESULTS: Fasting glucose levels increased significantly among women assigned to placebo but did not change among women receiving hormone therapy. The incidence of diabetes was 6.2% in the hormone therapy group and 9.5% in the placebo group (relative hazard, 0.65 [95% CI, 0.48 to 0.89]; P = 0.006). The number needed to treat for benefit to prevent one case of diabetes was 30 (CI, 18 to 103). Changes in weight and waist circumference did not mediate this effect. CONCLUSIONS: In women with coronary disease, hormone therapy reduced the incidence of diabetes by 35%. This observation provides important insights into the metabolic effects of postmenopausal hormones but is insufficient to recommend the use of hormones for secondary prevention of heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The majority of MHT trials have been done in women of normal weight (BMI<30); as such, the reported impact of MHT on body weight and adiposity has been modest (74, 204–206).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [205]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Nabulsi, A. A., Folsom, A. R., White, A., Patsch, W., Heiss, G., Wu, K. K., & Szklo, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304153281501 · Cited by 906
Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., Vittinghoff, E., Hulley, S., & for the Heart and Estrogen/progestin Replacement Study Research Group (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 715
Self-citationEstrogen in the Prevention of Atherosclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Hodis, H. N., Mack, W. J., Lobo, R. A., Shoupe, D., Sevanian, A., Mahrer, P. R., Selzer, R. H., Liu, C.-R., Liu, C.-H., Azen, S. P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00005 · Cited by 687
NACHTIGALL, L. E., NACHTIGALL, R. H., NACHTIGALL, R. D., & BECKMAN, M. E. (1979) · Obstetrics & Gynecology · doi:10.1097/00006250-197907000-00017 · Cited by 446
Mosca, L., Collins, P., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., Schenck-Gustafsson, K., Smith, Jr., Taubert, K. A., & Wenger, N. K. (2001) · Circulation · doi:10.1161/hc2901.092200 · Cited by 438
Self-citationEffects of long-term estrogen replacement therapy
Hammond, C. B., Jelovsek, F. R., Lee, K. L., Creasman, W. T., & Parker, R. T. (1979) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(79)90288-6 · Cited by 370
Research works printed but not linked: 10
- Lobo RA, 1994, Obstet Gynecol, 84, 987
- Kimmerle R, 1999, Menopause, 6, 36
- Vehkavaara S, 2000, J Clin Endocrinol Metab, 85, 4663
- Andersson B, 1997, J Clin Endocrinol Metab, 82, 638
- Friday KE, 2001, J Clin Endocrinol Metab, 86, 48
- Colacurci N, 1998, Panminerva Med, 40, 18
- 10.1002/(SICI)1520-7560(200001/02)16:1<20::AID-DMRR76>3.0.CO;2-A · doi:10.1002/(sici)1520-7560(200001/02)16:1<20::aid-dmrr76>3.0.co;2-a
- Cagnacci A, 1992, J Clin Endocrinol Metab, 74, 1396
- O'Sullivan AJ, 1995, J Clin Endocrinol Metab, 80, 1783
- Friend KE, 1996, J Clin Endocrinol Metab, 81, 2250
Cited by
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Metadata
- Authors
- Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E.
- Affiliations
- University of Pittsburgh (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-01-07
- Volume
- 138
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2141759136
- Cited by
- 633
- References
- 61
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 23 · 2023: 25 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 23 · 2018: 21 · 2017: 27 · 2016: 31 · 2015: 25 · 2014: 25 · 2013: 31 · 2012: 27
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hormone replacement therapy, conjugated estrogens, medroxyprogesterone acetate, new-onset diabetes, fasting blood glucose, coronary artery disease, diabetes prevention, secondary prevention, impaired fasting glucose
- MeSH terms
- Aged, Blood Glucose, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Estrogens, Conjugated (USP), Fasting, Female, Humans, Middle Aged, Placebos, Risk Factors, Estrogen Replacement Therapy, Incidence, Medroxyprogesterone Acetate, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.7326/0003-4819-138-1-200301070-00005
- The paper
- Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003). Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-1-200301070-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.